Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
$56.10
-0.3%
$59.28
$42.52
$62.89
$114.68B0.2610.27 million shs9.97 million shs
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$948.01
-2.8%
$943.90
$623.78
$1,133.95
$893.19B0.483.47 million shs3.24 million shs
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$111.26
-0.9%
$117.07
$73.31
$125.14
$275.09B0.189.36 million shs5.71 million shs
(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
-0.15%-3.68%-5.69%-9.50%+17.77%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
-2.75%-1.78%-0.89%-10.32%+22.02%
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
-0.86%-0.93%-9.47%-8.75%+40.67%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
$56.10
-0.3%
$59.28
$42.52
$62.89
$114.68B0.2610.27 million shs9.97 million shs
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$948.01
-2.8%
$943.90
$623.78
$1,133.95
$893.19B0.483.47 million shs3.24 million shs
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$111.26
-0.9%
$117.07
$73.31
$125.14
$275.09B0.189.36 million shs5.71 million shs
(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
-0.15%-3.68%-5.69%-9.50%+17.77%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
-2.75%-1.78%-0.89%-10.32%+22.02%
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
-0.86%-0.93%-9.47%-8.75%+40.67%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
2.37
Hold$61.319.30% Upside
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
2.87
Moderate Buy$1,218.3328.51% Upside
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
2.68
Moderate Buy$128.1815.21% Upside

Current Analyst Ratings Breakdown

Latest BMY, LLY, and MRK Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/7/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Boost Price Target$880.00 ➝ $900.00
5/6/2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Initiated CoverageNeutral$125.00
5/5/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Reiterated RatingBuy$1,183.00
5/4/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
UpgradeBuy (B-)Buy (B)
5/4/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Reiterated RatingOutperform$1,325.00
5/4/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Boost Price TargetOverweight$1,350.00 ➝ $1,400.00
5/1/2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Reiterated RatingHold (C+)
5/1/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Reiterated RatingOverweight$1,344.00
5/1/2026
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
Reiterated RatingNeutral
5/1/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Reiterated RatingOutperform
5/1/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Lower Price TargetBuy$1,294.00 ➝ $1,133.00
(Data available from 5/10/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
$48.19B2.38$8.12 per share6.91$9.09 per share6.17
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$65.18B13.70$25.13 per share37.73$28.07 per share33.77
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$65.01B4.23$11.41 per share9.75$21.22 per share5.24
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
$7.05B$3.5615.769.270.1615.01%64.87%13.16%N/A
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$20.64B$28.1533.6821.421.0334.98%105.77%23.76%N/A
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$18.25B$3.5531.3411.392.5113.59%27.55%10.73%N/A

Latest BMY, LLY, and MRK Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
4/30/2026Q1 2026
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
$1.42$1.58+$0.16$1.31$10.93 billion$11.49 billion
4/30/2026Q1 2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$6.97$8.55+$1.58$8.26$17.82 billion$19.80 billion
4/30/2026Q1 2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
-$1.47-$1.28+$0.19-$1.72$15.85 billion$16.29 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
$2.524.49%+1.61%70.79%17 Years
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$6.920.73%+15.18%24.58%11 Years
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$3.403.06%+5.75%95.77%14 Years

Latest BMY, LLY, and MRK Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
5/4/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
quarterly$1.730.72%5/15/20265/15/20266/10/2026
3/2/2026
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
quarterly$0.634.23%4/2/20264/2/20265/1/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
2.10
1.42
1.28
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
1.26
1.50
1.10
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
1.02
1.30
1.06

Institutional Ownership

CompanyInstitutional Ownership
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
76.41%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
82.53%
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
76.07%

Insider Ownership

CompanyInsider Ownership
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
0.05%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
0.14%
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
0.17%
CompanyEmployeesShares OutstandingFree FloatOptionable
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
32,5002.04 billion2.04 billionOptionable
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
50,000941.74 million940.42 millionOptionable
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
75,0002.47 billion2.47 billionOptionable

Recent News About These Companies

Ethic Inc. Boosts Holdings in Merck & Co., Inc. $MRK
Merck Faces Gardasil Trial After $8.9 Billion Sales Peak
How Hantavirus Made Moderna a Must-Own Stock Again
2 Dividend Stocks to Double Up On Right Now

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Bristol Myers Squibb stock logo

Bristol Myers Squibb NYSE:BMY

$56.10 -0.15 (-0.27%)
Closing price 05/8/2026 03:59 PM Eastern
Extended Trading
$56.21 +0.11 (+0.20%)
As of 05/8/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.

Eli Lilly and Company stock logo

Eli Lilly and Company NYSE:LLY

$948.01 -26.95 (-2.76%)
Closing price 05/8/2026 03:59 PM Eastern
Extended Trading
$950.10 +2.09 (+0.22%)
As of 05/8/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Merck & Co., Inc. stock logo

Merck & Co., Inc. NYSE:MRK

$111.26 -1.05 (-0.93%)
Closing price 05/8/2026 03:59 PM Eastern
Extended Trading
$111.84 +0.59 (+0.53%)
As of 05/8/2026 07:52 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.